Clue account plan
At a glance
Clue is a Berlin period and cycle tracking app; FY2024 revenue about 10.9 million, net loss 4.8 million, Verdane invested in January 2026.
Clue (BioWink GmbH, Berlin, founded 2012) makes a period and cycle tracking app with modes for cycle tracking, trying to conceive, pregnancy and perimenopause, and sells a paid tier, Clue Plus. It says it is used by over 100 million women and people with cycles; its strongest markets are the USA, UK, Germany, France, Australia and Canada. In FY2024 revenue rose to about 10.9 million (from 7 million) and the net loss fell to 4.8 million (from 8.2 million), with an average of 55 employees, according to a press report on its filed accounts. The company is privately held: it had raised almost 72 million by end-2024, and in January 2026 growth equity firm Verdane made what Clue calls the single largest investment in its history (stake and amount undisclosed). Rhiannon White, formerly Chief Product Officer, is CEO.
Strategic priorities
- Distribution through insurers, employers and partners
- Clue is building a network of partners across insurance, benefits and financial services that give Clue Plus to their members at no extra cost. In May 2026 German private health insurer SDK became the first insurer to cover it, joining Wellhub, Urban Sports Club, Klarna, Vodafone, Telefonica, Orange and US HSA/FSA-eligible benefits programs.
- Growth funded by Verdane
- After the January 2026 investment, Clue plans to accelerate product innovation, expand into new and existing markets, add healthcare partnerships, invest in clinical research, privacy-first technology and personalised care.
- Path to sustainable profitability
- The FY2024 accounts say break-even was reached by end-2024 but remaining funds were reinvested in new-user acquisition, with losses planned until about August 2025. Clue says 2025 created a clear path to long-term and sustainable profitability; the target for 2025 was revenue of 17 million.
- From period tracker to health companion
- The stated goal is to be a comprehensive health companion from the first period to the last, with more sophisticated tracking for life stages and conditions such as PCOS, endometriosis, PMDD and perimenopause.
- Research and data as a differentiator
- Users who opt in share de-identified data; Clue cites over 15 billion unique data points and over a million members contributing to its Health Record, with research partners including Stanford University, Johns Hopkins University and Berkeley.
Latest results
The latest stated full year is FY2024: revenue of about 10.9 million against 7 million in FY2023, and a net loss of 4.8 million against 8.2 million, with average headcount down to 55 from 94. Growth came from conversion optimisation of the Clue Period Tracker v2 app, marketing of new modes and CRM and discount campaigns; B2B already made up over 6% of total monthly revenue. The company targeted 17 million revenue for 2025. In May 2025 the CEO said Clue pays its own bills and no longer needs investors' money, and Clue described 2025 as exceptional when announcing the Verdane investment in January 2026; no 2025 figures are published in these documents.
Investments and deals
- Verdane growth investment (January 2026)
- Investment from Verdane's €2 billion growth fund, described as the single largest in Clue's history; amount and stake not disclosed.
- SDK insurance partnership (May 2026)
- Clue Plus offered at no extra cost to thousands of SDK fully insured members and the roughly 1,600 employees of SDK and Stuttgarter Lebensversicherung a. G.
- New-user acquisition
- Funds remaining after break-even at end-2024 were reinvested directly in new-user acquisition, per the FY2024 accounts.
Challenges and risks
- Long loss-making history
- Building Clue has cost about 63.1 million in total, against almost 72 million raised by end-2024; FY2024 still closed with a net loss of 4.8 million.
- Smaller team after cuts
- Average headcount fell from 117 to 94 to 55 over three years as the company cut costs mainly by reducing staff.
- Underserved and confusing women's health market
- Clue's CEO describes a lack of accessible female health knowledge, a marketplace of unproven products and barriers to care; in a survey of almost 12,000 users, two thirds report concerns about their menstrual health.
- Conversion-driven subscription revenue
- FY2024 growth relied on conversion optimisation, CRM and discount campaigns, while user acquisition approaches were still being tested month by month in 2025.
What leadership says
“we're paying our own way. We pay our own bills. We don't need to take investors' money any more”
“building a network of partners across insurance, benefits, and financial services”
“the P&L is revealed strategy”
“Trust is fundamental to everything we do at Clue”
Where a supplier can help
- Benefits and insurance channel partners
- Tied to the distribution priority: insurers, employee-benefits platforms, telcos and financial-services firms that want to add a women's health benefit fit the partner network Clue is building after SDK.
- User acquisition and conversion tooling
- Tied to the reinvestment in new-user acquisition and the conversion, CRM and discount campaigns behind FY2024 growth: performance marketing, experimentation and CRM vendors.
- Privacy and security technology
- Tied to the Verdane-funded privacy-first technology priority and Clue's positioning on data protection.
- Clinical research partnerships
- Tied to the research priority: research institutions and data partners working on PCOS, endometriosis, PMDD or perimenopause.
- International expansion support
- Tied to the plan to scale new and existing markets with Verdane's investment: localisation, payments and market-entry services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Clue?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Clue Becomes the First Insurance-Covered Period and Menstrual Cycle Tracker in the World (SDK partnership press release)
- Clue announced a partnership with Süddeutsche Krankenversicherung a. G. (SDK), one of Germany's leading private health insurers, presented as making Clue the first period and menstrual cycle tracker in the world to be covered by health insurance.
- Thousands of SDK's fully insured members, plus the roughly 1,600 employees of SDK and Stuttgarter Lebensversicherung a. G., get Clue Plus at no extra cost.
- The deal is part of a broader push to distribute Clue Plus through partners women already use: Wellhub, Urban Sports Club, Klarna, Vodafone, Telefonica, Orange and HSA/FSA-eligible benefits programs in the United States.
- CEO Rhiannon White says Clue is "building a network of partners across insurance, benefits, and financial services" and hopes "to see more insurers follow".
- Clue describes itself as the #1 women-led period and cycle tracker, loved by over 100 million women and people with cycles.
- Product scope: tailored modes for period and cycle tracking, trying to conceive, pregnancy monitoring and perimenopause, plus educational content.
- A survey of almost 12,000 Clue users found two thirds report concerns about their menstrual health (preliminary data, publication under review).
- Verdane partners with Clue to accelerate the future of women's health (investment announcement)
- Verdane, a European specialist growth equity firm, invested in Clue from its €2 billion growth fund; Clue calls it "the single largest in Clue's history" (amount not disclosed).
- The deal follows "an exceptional 2025" which, per Clue, created "a clear path to long-term and sustainable profitability".
- Use of funds: product innovation, expanded global reach (new and existing markets), healthcare partnerships, clinical research, privacy-first technology and personalised care.
- CEO Rhiannon White frames women's health as "a significant market failure" and an opportunity to serve "the most influential spenders in global health and wellness".
- Christina Stoll, Principal at Verdane, cites "the strong momentum the business is demonstrating" and Clue's user trust built on data protection and science.
- Verdane can invest as majority or minority investor; it has raised over €9 billion and made more than 200 investments since 2003 (the release does not state the stake taken in Clue).
- Clue FY2024 annual accounts: revenue up to about 10.9 million (deutsche-startups.de Zahlencheck)
- Press report (in German) on BioWink GmbH's (Clue) filed annual accounts (Jahresabschluss) for FY2024; the accounts themselves were not read.
- Revenue rose to about 10.9 million (prior year: 7 million); net loss (Jahresfehlbetrag) fell to 4.8 million from 8.2 million.
- Growth drivers per the company: conversion optimisation of the Clue Period Tracker v2 ("Rebirth") app, marketing of the new modes, and ongoing CRM and discount campaigns.
- B2B business is growing and already makes up over 6% of total monthly revenue (translation).
- Strongest markets: the USA, UK, Germany, France, Australia and Canada.
- Average headcount fell to 55 in 2024, from 94 in 2023 and 117 the year before.
- Targeted revenue for 2025: 17 million. The accounts say break-even was reached by end-2024, but remaining funds were reinvested in new-user acquisition, with losses planned until about August 2025, covered by the liquidity reserve.
- Cumulative cost of building Clue (founded 2012): about 63.1 million; capital raised by end-2024: almost 72 million.
- From Product to CEO: Leading Beyond Execution (UXDX EMEA 2025 fireside chat, transcript)
- Fireside chat at UXDX EMEA 2025 (19 May) between Clue CEO Rhiannon White, formerly Chief Product Officer, and UXDX founder Rory Madden; full readable transcript published.
- Financial position: "we're paying our own way. We pay our own bills. We don't need to take investors' money any more", after "a bit of a roller coaster" and a "cold winter in tech since 22".
- Clue got smaller over the downturn; White describes it as "not a large company" and "in a great place now".
- She reports to the board monthly on results, and was running a one-month test on user acquisition (UA) in May.
- Management mantra: "numbers up, people down": boards "care about the language of capital"; "the P&L is revealed strategy".
- She still runs a long-form user interview every week and pushes marketing and other teams to hear users directly.
- Product example: a tracking option for women with hormonal cycles but no periods, shipped "at the end of last year".
- She is sceptical of "founder mode", "taste" and north star metrics, and of reorienting the product around conversational UI because an investor suggests it.
- Clue's CEO Rhiannon White on the Future of Femtech and PCOS (News-Medical interview)
- Written interview with Rhiannon White shortly after she became CEO; she joined Clue in 2022 as Chief Product Officer, after Shazam, Vend and the BBC.
- Mission unchanged: "to empower women and people with cycles to take charge of their health with no myths, no taboos, and no barriers."
- Research asset: Clue cycle data from users who opt in, "already over 15 billion unique data points"; the Health Record feature launched in 2023 has data from over a million members.
- Research partners named: Stanford University, Johns Hopkins University, Berkeley and others; focus on PCOS, endometriosis, PMDD and perimenopause.
- Partnership: a collaboration with Headspace launched "over the summer" combining cycle insights with mental health resources.
- Product direction: from period tracker to "a comprehensive health companion" from first period to last, with more sophisticated tracking for life stages and conditions.
- Positioning: trust, scientific integrity, data privacy; "medical-grade standards in our product development is non-negotiable".
Questions about Clue
What does Clue do?
Clue makes a period and cycle tracking app from Berlin, with modes for cycle tracking, trying to conceive, pregnancy and perimenopause, and a paid tier, Clue Plus. It also uses opted-in, de-identified data for women's health research.
What is Clue's revenue?
According to a press report on its filed accounts, revenue was about 10.9 million in FY2024, up from 7 million in FY2023, with a net loss of 4.8 million. The company targeted 17 million for 2025.
How many employees does Clue have?
Average headcount was 55 in FY2024, down from 94 in 2023 and 117 the year before.
Who owns Clue?
Clue (BioWink GmbH) is privately held, having raised almost 72 million by end-2024. In January 2026 Verdane invested from its €2 billion growth fund; the stake was not disclosed.
Who leads Clue?
Rhiannon White is CEO; she joined in 2022 as Chief Product Officer after roles at Shazam, Vend and the BBC.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)